353 related articles for article (PubMed ID: 30850035)
1. What's New in Hair Loss.
Santos LDN; Shapiro J
Dermatol Clin; 2019 Apr; 37(2):137-141. PubMed ID: 30850035
[TBL] [Abstract][Full Text] [Related]
2. Janus kinase inhibitors: An innovative treatment for alopecia areata.
Park H; Yu DA; Kwon O
J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
[TBL] [Abstract][Full Text] [Related]
3. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
[TBL] [Abstract][Full Text] [Related]
4. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Almutairi N; Nour TM; Hussain NH
Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
[TBL] [Abstract][Full Text] [Related]
5. The Good and Bad News About New Drugs for Treating Alopecia Areata.
Morgado-Carrasco D; RodrÃguez-Lobato E; Riera-Monroig J; Ferrando J
Actas Dermosifiliogr (Engl Ed); 2018; 109(1):69-70. PubMed ID: 28641742
[No Abstract] [Full Text] [Related]
6. Oral Baricitinib Restores Hair Loss in Alopecia Areata.
Slomski A
JAMA; 2022 Jun; 327(24):2386. PubMed ID: 35762995
[No Abstract] [Full Text] [Related]
7. JAK Inhibitors for the Treatment of Pediatric Alopecia Areata.
Hamilton CE; Craiglow BG
J Investig Dermatol Symp Proc; 2020 Nov; 20(1):S31-S36. PubMed ID: 33099381
[TBL] [Abstract][Full Text] [Related]
8. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J
J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121
[TBL] [Abstract][Full Text] [Related]
9. Review of the use of Janus kinase inhibitors in the treatment of scarring alopecia.
Nohria A; Desai D; Shapiro J; Bordone L; Lo Sicco K
Int J Dermatol; 2024 Jun; 63(6):e105-e110. PubMed ID: 38571280
[No Abstract] [Full Text] [Related]
10. Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
Salman A; Sarac G; Ergun T
Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469706
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
[TBL] [Abstract][Full Text] [Related]
12. Baricitinib in Alopecia Areata.
Messenger A; Harries M
N Engl J Med; 2022 May; 386(18):1751-1752. PubMed ID: 35507486
[No Abstract] [Full Text] [Related]
13. Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata.
Gordon SC; Abudu M; Zancanaro P; Ko JM; Rosmarin D
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e156-e157. PubMed ID: 30520145
[No Abstract] [Full Text] [Related]
14. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
King B; Guttman-Yassky E; Peeva E; Banerjee A; Sinclair R; Pavel AB; Zhu L; Cox LA; Craiglow B; Chen L; Banfield C; Page K; Zhang W; Vincent MS
J Am Acad Dermatol; 2021 Aug; 85(2):379-387. PubMed ID: 33757798
[TBL] [Abstract][Full Text] [Related]
15. Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
Bokhari L; Sinclair R
Int J Dermatol; 2018 Dec; 57(12):1464-1470. PubMed ID: 30160787
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib for the treatment of alopecia areata in preadolescent children.
Craiglow BG; King BA
J Am Acad Dermatol; 2019 Feb; 80(2):568-570. PubMed ID: 30195571
[No Abstract] [Full Text] [Related]
17. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents.
Liu LY; King BA
J Investig Dermatol Symp Proc; 2018 Jan; 19(1):S18-S20. PubMed ID: 29273099
[TBL] [Abstract][Full Text] [Related]
18. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.
Bayart CB; DeNiro KL; Brichta L; Craiglow BG; Sidbury R
J Am Acad Dermatol; 2017 Jul; 77(1):167-170. PubMed ID: 28619556
[No Abstract] [Full Text] [Related]
19. Janus kinase inhibitors in dermatology: A systematic review.
Shreberk-Hassidim R; Ramot Y; Zlotogorski A
J Am Acad Dermatol; 2017 Apr; 76(4):745-753.e19. PubMed ID: 28169015
[TBL] [Abstract][Full Text] [Related]
20. Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib.
Fetter T; Rios GC; Niebel D; Bieber T; Wenzel J
Acta Derm Venereol; 2020 May; 100(10):adv00144. PubMed ID: 32285135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]